New hope for rare cancer: drug cocktail targets sarcoma
NCT ID NCT05926700
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase 2 trial tests whether two drugs, cadonilimab and anlotinib, can help people with advanced or metastatic soft tissue sarcoma whose first treatment stopped working. About 27 adults will receive the combination to see if it slows tumor growth. The study is currently recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- cadonilimab and anlotinib
- What this could lead to
- If successful, this combination could offer a new treatment option for people with advanced soft tissue sarcoma who have run out of standard options.
- What could go wrong
- This is a small, early-phase trial with only 27 participants, so results may not apply to everyone. The combination may cause side effects and might not work better than existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOFT TISSUE SARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Second Affiliated Hospital, Zhejiang University School of Medicine
RECRUITINGHangzhou, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive antibody light up hidden tumors?
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- Could a massive tissue bank unlock sarcoma's secrets?
- Can a targeted pill stall advanced sarcomas?
- Protein-Wrapped chemo aims to hit tumors harder, spare healthy cells
- Drug duo takes on rare head and neck tumors